Kenneth Allen Myszkowski is Chief Financial Officer of ARROWHEAD PHARMACEUTICALS, INC.. Currently has a direct ownership of 400,600 shares of ARWR, which is worth approximately $10 Million. The most recent transaction as insider was on Mar 06, 2024, when has been sold 40,000 shares (Common Stock) at a price of $35.19 per share, resulting in proceeds of $1,407,600. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 401K
0% 3M change
4.95% 12M change
Total Value Held $10 Million

Kenneth Allen Myszkowski Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 06 2024
SELL
Open market or private sale
$1,407,600 $35.19 p/Share
40,000 Reduced 9.08%
400,600 Common Stock
Jan 05 2024
SELL
Open market or private sale
$561,868 $34.89 p/Share
16,104 Reduced 3.53%
440,600 Common Stock
Jan 04 2024
BUY
Grant, award, or other acquisition
-
75,000 Added 14.11%
456,704 Common Stock
Jun 27 2023
SELL
Open market or private sale
$543,000 $36.2 p/Share
15,000 Reduced 3.78%
381,704 Common Stock
Jan 04 2023
BUY
Grant, award, or other acquisition
-
60,000 Added 13.14%
396,704 Common Stock
Dec 29 2022
SELL
Open market or private sale
$1,225,000 $40.0 p/Share
30,625 Reduced 8.34%
336,704 Common Stock
Jan 05 2022
SELL
Open market or private sale
$2,496,400 $62.41 p/Share
40,000 Reduced 7.94%
464,005 Common Stock
Jan 01 2022
BUY
Grant, award, or other acquisition
-
60,000 Added 10.64%
504,005 Common Stock
Jan 12 2021
SELL
Open market or private sale
$116,721 $81.0 p/Share
1,441 Reduced 0.32%
444,005 Common Stock
Jan 11 2021
SELL
Open market or private sale
$939,589 $81.02 p/Share
11,597 Reduced 2.54%
445,446 Common Stock
Jan 06 2021
SELL
Open market or private sale
$2,196,425 $71.72 p/Share
30,625 Reduced 6.28%
457,043 Common Stock
Jan 01 2021
BUY
Grant, award, or other acquisition
-
60,000 Added 10.96%
487,668 Common Stock
Nov 09 2020
SELL
Open market or private sale
$3,021,422 $69.45 p/Share
43,505 Reduced 9.23%
427,668 Common Stock
Nov 09 2020
BUY
Exercise of conversion of derivative security
$632,563 $14.54 p/Share
43,505 Added 8.45%
471,173 Common Stock
Oct 20 2020
SELL
Open market or private sale
$1,576,131 $54.04 p/Share
29,166 Reduced 6.38%
427,668 Common Stock
Oct 20 2020
BUY
Exercise of conversion of derivative security
$179,371 $6.15 p/Share
29,166 Added 6.0%
456,834 Common Stock
KAM

Kenneth Allen Myszkowski

Chief Financial Officer
Pasadena, CA

Track Institutional and Insider Activities on ARWR

Follow ARROWHEAD PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARWR shares.

Notify only if

Insider Trading

Get notified when an Arrowhead Pharmaceuticals, Inc. insider buys or sells ARWR shares.

Notify only if

News

Receive news related to ARROWHEAD PHARMACEUTICALS, INC.

Track Activities on ARWR